BriaCell Therapeutics Corp

BriaCell Therapeutics Corp. is a pre-clinical stage immuno-oncology company focused on developing targeted immunotherapies to transform cancer care. Its lead candidate, Bria-IMT, is a targeted immunotherapy for end-stage breast cancer currently in Phase 3 clinical trials. The company is also developing Bria-OTS, a personalized off-the-shelf immunotherapy, and a soluble CD80 protein therapeutic that acts as an immune system stimulator and immune checkpoint inhibitor. BriaCell has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for cancer treatment, and a collaboration with MSK Accelerator to accelerate clinical development of Bria-OTS+ for multiple cancer indications, including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.